| Literature DB >> 21623310 |
Zhi-Jun Dai1, Jie Gao, Zong-Fang Li, Zong-Zheng Ji, Hua-Feng Kang, Hai-Tao Guan, Yan Diao, Bao-Feng Wang, Xi-Jing Wang.
Abstract
In the present study, we investigated the in vitro and in vivo antitumor effects of crude extract of Scutellaria Barbate (CE-SB) on mouse hepatoma H22 cells. The MTT assay was used to determine the growth inhibition of H22 cells in vitro. The in vivo therapeutic effects of CE-SB were determined using H22 tumor bearing mice. Besides, the body weight, tumor weight, thymus index and spleen index of H22 bearing mice were also measured. The tumor inhibitory rate (IR) was calculated according to the mean weight of tumor (MWT). The phagocytotic function of macrophages was examined by observing peritoneal macrophages phagocytize chicken RBC. The results showed that CE-SB could inhibit the growth of hepatoma H22 Cells in vitro and in vivo. Furthermore, CE-SB could improve immune function of H22 tumor bearing mice. Together these results indicate that CE-SB has antitumor activity and seems to be safe and effective for the use of anti-tumor therapy.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21623310 PMCID: PMC6264136 DOI: 10.3390/molecules16064389
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Photograph of Scutellaria barbata D. Don.
Figure 2Growth inhibiting effects of CE-SB on hepatoma H22 cells. H22 cells were treated with low-high dose of CE-SB for 96 h. Dose- and time-dependent inhibition of H22 cell growth could be observed (P < 0.05, ANOVA analysis). Cells were incubated with different dosages of CE-SB and cell proliferation was determined by MTT assay.
Figure 3Morphological observation of H22 cells by EM after treatment. The cells were examined under a transmission electronmicroscope (×5000 power, bar = 1 μm). A: normal hepatoma H22 cells; B: karyopyknosis, membrane integrity and formation of apoptotic bodies in high dosage CE-SB group.
Effects of CE-SB on body weight and tumor weight of H22 bearing mice ( ± s, n = 10).
| Group | Dosage (g/kg/d) | Body weight(g) | Variation of body weight (g) | Tumor weight (g) | Tumor inhibition rate (%) | |
|---|---|---|---|---|---|---|
| Pre-treatment Post-treatment | ||||||
| Normal | - | 20.03 ± 1.94 | 24.12 ± 2.02 # | 4.09 ± 2.32 # | - | - |
| Tumor control | - | 20.03 ± 2.07 | 23.50 ± 3.24 # | 3.47 ± 3.82 # | 2.65 ± 1.12 # | - |
| 5-FU | 0.02 | 19.96 ± 2.03 | 20.74 ± 1.86 * | 0.78 ± 1.93 * | 1.53 ± 0.64 * | 42.26 |
| CE-SB | 3 | 20.00 ± 1.94 | 24.52 ± 1.82 # | 4.52 ± 3.93 # | 2.27 ± 0.93 # | 14.34 |
| 6 | 19.93 ± 2.12 | 24.77 ± 1.98 # | 4.84 ± 3.62 #* | 1.89 ± 0.82 *# | 28.68 | |
| 12 | 20.01 ± 2.10 | 25.15 ± 2.13 # | 5.14 ± 3.76 *# | 1.67 ± 0.76 * | 36.98 | |
* P < 0.05 vs. tumor control group; # P < 0.05 vs. 5-FU group
Figure 4Influence of CE-SB on immune organs and WBC count of H22 bearing mice. Group A: normal control; Group B: tumor control; Group C: 5-FU; Group D: low dosage CE-SB; Group E: medium dosage CE-SB; Group F: high dosage CE-SB. * P < 0.05 vs. tumor control group; # P < 0.05 vs. 5-FU group.
Figure 5Influence of CE-SB on phagocytotic function of macrophage of H22 bearing mice. Group A: normal control; Group B: tumor control; Group C: 5-FU; Group D: low dosage CE-SB; Group E: medium dosage CE-SB; Group F: high dosage CE-SB. * P < 0.05 vs. tumor control group; # P < 0.05 vs. 5-FU group.